Alnylam Pharmaceuticals Croissance future
Future contrôle des critères 5/6
Alnylam Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 28.3% et de 19.5% par an respectivement. Le BPA devrait croître de de 27.1% par an. Le rendement des capitaux propres devrait être 39% dans 3 ans.
Informations clés
28.3%
Taux de croissance des bénéfices
27.12%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 25.4% |
| Taux de croissance des recettes | 19.5% |
| Rendement futur des capitaux propres | 38.97% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 27 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • May 11
ALNY: Fair View Weighs TTR Execution Risks Against Cardiovascular Pipeline Progress
Analysts have nudged Alnylam Pharmaceuticals' fair value estimate to $311.72 from $310.00, reflecting updated assumptions for slightly lower revenue growth and profit margins, as well as a higher future P/E multiple based on recent shifts in price targets and commentary across the Street. Analyst Commentary Recent research has highlighted a mixed backdrop for Alnylam Pharmaceuticals, with some firms revising targets higher on product execution while others voice concern that the stock already reflects optimistic outcomes.Seeking Alpha • May 01
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
Summary Alnylam Pharmaceuticals remains well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset generation. Q1 2026 results showed 150% year-over-year TTR franchise growth despite insurance and pricing headwinds; Amvuttra continues to gain front-line share. ALNY maintains full-year TTR revenue guidance of $4.4B–$4.7B, with ongoing investments in earlier diagnosis and care coordination to expand the addressable market. Second-half updates on early-stage compounds for bleeding disorders, Huntington's, and obesity could drive more market interest. I see ALNY shares as meaningfully undervalued, supported by pipeline progress and a resilient TTR franchise, though major clinical catalysts are likely deferred. Read the full article on Seeking AlphaMise à jour du récit • Apr 20
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.
Mise à jour du récit • Apr 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.Mise à jour du récit • Mar 23
ALNY: TTR Franchise Momentum Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' updated analyst price targets show a wide reset across the Street, with cuts from firms now clustered around the $249 to $570 range. Analysts are balancing strong Amvuttra momentum and the RNAi platform's potential with concerns that the shares had been priced for very optimistic growth and competition assumptions.Mise à jour du récit • Mar 07
ALNY: TTR Execution Will Support Confidence In 2026 Revenue Outlook
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals by $14 to $566, reflecting higher discount rates and more conservative assumptions for revenue growth and profit margins, even as they continue to highlight strong Amvuttra traction and supportive 2026 guidance in recent research. Analyst Commentary Recent research paints a mixed picture on valuation, but there is still a clear cluster of optimistic views around Alnylam's execution, especially in its TTR franchise and Amvuttra rollout.Mise à jour du récit • Feb 21
ALNY: Fair View Weighs TTR Franchise Guidance Against Launch Execution Risks
The updated analyst price target for Alnylam Pharmaceuticals has decreased by about $45 per share, as analysts refresh their models with slightly softer revenue growth assumptions, a modestly higher long-term profit margin, and a reduced future P/E multiple. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed backdrop, with several firms revisiting their models following Q4 results, preannounced revenue figures, and updated 2026 guidance.Mise à jour du récit • Feb 06
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Guidance
Analysts have trimmed their average price targets on Alnylam Pharmaceuticals by roughly $35 to $70, largely reflecting updated views on Amvuttra revenue trajectories, competitive pressures in ATTR-CM and recent guidance that, while still supported by continued TTR franchise momentum, has prompted more measured growth assumptions. Analyst Commentary Recent research updates show a mixed but generally constructive tone on Alnylam, with several bullish analysts pointing to execution on the TTR franchise, early Amvuttra traction in ATTR-CM and management guidance as key supports for valuation.Mise à jour du récit • Jan 23
ALNY: TTR Franchise Momentum Will Drive 2026 Revenue Guidance Confidence
Narrative Update: Alnylam Pharmaceuticals Price Target Revision The analyst price target for Alnylam Pharmaceuticals has been raised by $10 to $580, as analysts weigh mixed target changes across the Street alongside company guidance that highlights ongoing momentum in the TTR franchise and a positive outlook for revenue driven by Amvuttra. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has been active, with several price target revisions and fresh commentary following the company’s Q3 results, preliminary Q4 figures, and updated 2025 and 2026 revenue guidance.Mise à jour du récit • Jan 09
ALNY: Fair View Balances TTR Guidance Upside And Launch Deceleration Risk
Alnylam Pharmaceuticals' analyst fair value estimate has been raised from about $259.89 to about $368.22, as analysts factor in stronger modeled revenue growth, higher projected profitability, and a reset to more moderate future P/E expectations following recent research updates around Amvuttra uptake and revised TTR guidance. Analyst Commentary Recent research on Alnylam highlights a mixed backdrop.
Mise à jour du récit • Dec 26
ALNY: Cardiomyopathy Launch Will Drive Future Upside Despite Growing Competitive Pressures
Analysts have modestly lifted their price target for Alnylam Pharmaceuticals, reflecting stronger Amvuttra driven TTR revenue expectations and a series of Street target increases into the mid 400s to mid 500s, even as they highlight a more balanced risk and the potential for range bound trading into 2026. Analyst Commentary Recent Street research reflects a constructive but increasingly balanced view on Alnylam, with multiple firms lifting price targets into the mid 400s to mid 500s on the back of stronger Amvuttra traction and higher TTR revenue expectations, while also flagging valuation and competitive considerations that could cap upside.Mise à jour du récit • Dec 12
ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition
Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.Mise à jour du récit • Nov 27
ALNY: Future Momentum In Cardiomyopathy Will Meet Rising Competition And Pricing Pressures
The analyst price target for Alnylam Pharmaceuticals has increased by approximately $9 to $489, as analysts cite strong Amvuttra sales, raised revenue guidance, and resilient commercial momentum as key factors supporting a more optimistic outlook. Analyst Commentary Analysts have provided a range of perspectives following Alnylam Pharmaceuticals’ recent performance, with several raising their price targets and highlighting both catalysts and areas of caution for the company’s outlook.Mise à jour du récit • Nov 12
ALNY: Momentum In Cardiomyopathy Segment Will Face Intensifying Competitive Risks Ahead
Alnylam Pharmaceuticals’ fair value estimate has increased from $467.94 to $480.17. This change reflects analysts' optimism about robust Amvuttra sales, raised revenue guidance, and an improved profit margin outlook.Mise à jour du récit • Oct 29
Cardiomyopathy Launches And Pipeline Expansion Will Sustain Momentum Into 2025
Analysts have increased their price target for Alnylam Pharmaceuticals by approximately $16, citing stronger than expected product launches and continued commercial momentum. Analyst Commentary Following a series of upward price target revisions, Wall Street analysts remain broadly upbeat about Alnylam Pharmaceuticals’ near-term commercial performance and long-term prospects.Mise à jour du récit • Oct 14
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals' analyst price targets have recently moved higher, with analysts citing stronger commercial performance of Amvuttra and encouraging data from pipeline assets as drivers behind the upward revisions. The cited targets have climbed by as much as $55 to $583 per share.Mise à jour du récit • Sep 23
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.Mise à jour du récit • Sep 08
RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam’s modestly lower consensus price target to $421.20 reflects both strong near-term Amvuttra uptake in ATTR-CM and positive revenue outlook, tempered by mixed KARDIA-3 data for zilebesiran and resulting slight valuation adjustment. Analyst Commentary Bullish analysts cited strong commercial performance and encouraging uptake for Amvuttra, particularly following its approval and launch in ATTR-CM (transthyretin amyloid cardiomyopathy), as a key driver for raising price targets.Article d’analyse • Aug 01
Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Mar 21
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Summary Alnylam Pharmaceuticals has secured FDA approval for Amvuttra in ATTR-CM, opening the door to potential revenue of over $6B. The company's strong R&D pipeline, including promising candidates like zilebesiran, supports long-term growth and will reduce its heavy near-term reliance on the TTR franchise. Amvuttra is likely to see strong initial adoption in ATTR-CM patients who've progressed on stabilizers, but greater first-line use and switchovers could drive the upside. Alnylam's proven R&D engine and above-average success ratio make it a compelling long-term biotech investment despite arguably modest immediate upside. Read the full article on Seeking AlphaSeeking Alpha • Feb 13
Alnylam: Waiting For Regulatory Updates In March
Summary Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR franchise implies modest growth acceleration compared to 2024, driven by Amvuttra's expected approval next month. Fitusiran's approval could result in meaningful annual royalties for Alnylam from partner Sanofi, enhancing long-term profitability and cash flows. Alnylam expects non-GAAP operating profitability in 2025. Successful regulatory approvals and strong commercial execution could push Alnylam's share price to new all-time highs within 6–12 months. Read the full article on Seeking AlphaSeeking Alpha • Oct 27
Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Summary Alnylam Pharmaceuticals is a leader in RNAi therapeutics, with multiple FDA-approved treatments and a robust pipeline targeting rare and severe conditions. The company has strong growth potential, particularly with Amvuttra for ATTR-CM, which could become a major revenue driver in a growing market. Additionally, vutrisiran for ATTR-CM could capture a significant share of a projected $11.2 billion market. Regulatory risks and competition exist, but ALNY's innovative RNAi platform and experienced team position it well for sustained success. Despite a high valuation, ALNY's positive cash flow and projected revenue growth justify a "Buy on dips" strategy for long-term investors. Read the full article on Seeking AlphaSeeking Alpha • Aug 30
Alnylam: HELIOS-B Success Priced In Already
Summary Alnylam's stock surged due to positive HELIOS-B trial results, but lacked additional upside today after the company presented the data at the ESC congress. Amvuttra shows competitive efficacy and safety in ATTR amyloidosis, with potential to rival Pfizer’s Vyndaqel and other emerging treatments. I believe HELIOS-B's success is priced in at current levels and that further upside is limited in the near-term. I remain a long-term bull on Alnylam based on its expanding and maturing RNAi pipeline. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 8,721 | 1,983 | 2,428 | 2,392 | 21 |
| 12/31/2027 | 7,300 | 1,520 | 1,930 | 1,893 | 26 |
| 12/31/2026 | 5,611 | 1,026 | 1,335 | 1,274 | 27 |
| 3/31/2026 | 4,287 | 538 | 643 | 715 | N/A |
| 12/31/2025 | 3,714 | 314 | 465 | 524 | N/A |
| 9/30/2025 | 3,210 | 83 | 219 | 264 | N/A |
| 6/30/2025 | 2,462 | -280 | -54 | -18 | N/A |
| 3/31/2025 | 2,348 | -230 | -77 | -47 | N/A |
| 12/31/2024 | 2,248 | -278 | -43 | -8 | N/A |
| 9/30/2024 | 2,095 | -332 | 16 | 57 | N/A |
| 6/30/2024 | 2,344 | -73 | 319 | 372 | N/A |
| 3/31/2024 | 2,003 | -332 | 128 | 189 | N/A |
| 12/31/2023 | 1,828 | -440 | 42 | 104 | N/A |
| 9/30/2023 | 1,724 | -510 | -67 | 2 | N/A |
| 6/30/2023 | 1,237 | -1,064 | -541 | -473 | N/A |
| 3/31/2023 | 1,143 | -1,065 | -605 | -537 | N/A |
| 12/31/2022 | 1,037 | -1,131 | -613 | -541 | N/A |
| 9/30/2022 | 961 | -1,182 | -632 | -559 | N/A |
| 6/30/2022 | 884 | -981 | -660 | -578 | N/A |
| 3/31/2022 | 880 | -893 | -654 | -577 | N/A |
| 12/31/2021 | 844 | -853 | -718 | -642 | N/A |
| 9/30/2021 | 749 | -838 | -691 | -615 | N/A |
| 6/30/2021 | 688 | -887 | -653 | -591 | N/A |
| 3/31/2021 | 571 | -876 | -672 | -604 | N/A |
| 12/31/2020 | 493 | -858 | -685 | -615 | N/A |
| 9/30/2020 | 401 | -891 | -775 | -688 | N/A |
| 6/30/2020 | 345 | -846 | -871 | -760 | N/A |
| 3/31/2020 | 286 | -886 | -452 | -336 | N/A |
| 12/31/2019 | 220 | -886 | N/A | -278 | N/A |
| 9/30/2019 | 169 | -821 | N/A | -233 | N/A |
| 6/30/2019 | 101 | -858 | N/A | -204 | N/A |
| 3/31/2019 | 86 | -802 | N/A | -595 | N/A |
| 12/31/2018 | 75 | -761 | N/A | -563 | N/A |
| 9/30/2018 | 92 | -692 | N/A | -515 | N/A |
| 6/30/2018 | 107 | -570 | N/A | -460 | N/A |
| 3/31/2018 | 93 | -525 | N/A | -438 | N/A |
| 12/31/2017 | 90 | -491 | N/A | -383 | N/A |
| 9/30/2017 | 69 | -462 | N/A | -358 | N/A |
| 6/30/2017 | 66 | -443 | N/A | -335 | N/A |
| 3/31/2017 | 59 | -414 | N/A | -324 | N/A |
| 12/31/2016 | 47 | -410 | N/A | -308 | N/A |
| 9/30/2016 | 37 | -388 | N/A | -282 | N/A |
| 6/30/2016 | 30 | -361 | N/A | -261 | N/A |
| 3/31/2016 | 30 | -342 | N/A | -247 | N/A |
| 12/31/2015 | 41 | -290 | N/A | -189 | N/A |
| 9/30/2015 | 58 | -221 | N/A | -173 | N/A |
| 6/30/2015 | 62 | -188 | N/A | -159 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ALNY ( 28.3% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de ALNY ( 28.3% par an) devraient croître plus rapidement que le marché US ( 17% par an).
Croissance élevée des bénéfices: Les bénéfices de ALNY devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de ALNY ( 19.5% par an) devrait croître plus rapidement que le marché US ( 11.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de ALNY ( 19.5% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de ALNY devrait être élevé dans 3 ans ( 39 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/31 06:04 |
| Cours de l'action en fin de journée | 2026/05/29 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Alnylam Pharmaceuticals, Inc. est couverte par 57 analystes. 27 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Emily Bodnar | Berenberg |